Company Filing History:

6 out of 20

Societe Civile Bioprojet

patents

2 out of 1,744

Institut National De La Sante Et De La Recherche Medicale

Societe Civile Bioproject

patents

5. 1 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2006

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7094773 - [object Object] (2006-08-22),

2. 6878723 - LTA4 hydrolase inhibitors (2005-04-12),

3. 6835851 - Process for synthesizing N-(mercaptoacyl) amino acid derivatives from alpha-substituted acrylic acids (2004-12-28),

4. 6436973 - LTA4 hydrolase inhibitors (2002-08-20),

5. 6013829 - Process for the asymmetric synthesis of S-acyl derivatives of (2000-01-11),

6. 5945548 - Process for the synthesis of .alpha.-substituted acrylic acids and their (1999-08-31),

7. 5846956 - Amino acids derivatives, the process for their preparation and their (1998-12-08),

8. 5786494 - Process for the synthesis of .alpha.-substituted acrylic acids and their (1998-07-28),

9. 5670531 - Amino acid derivatives, the process for their preparation and their (1997-09-23),

10. 5646313 - Amino acid derivatives, processes for their preparation and their (1997-07-08),

11. 5612371 - Amino acid, derivatives, processes for their preparation and their (1997-03-18),

12. 5599951 - Amino acid derivatives, the process for their preparation and their (1997-02-04),

Title: The Innovative Contributions of Thierry Monteil

Introduction: Thierry Monteil is a notable inventor based in Saint Georges sur Fontaine, France. With a remarkable portfolio of 12 patents, he has made significant advancements in the field of medicinal compounds, particularly focusing on anti-inflammatory activities. His work highlights the intersection of chemistry and therapeutic applications.

Latest Patents: Among Thierry Monteil's most recent inventions are compounds that function as a class of medicaments with anti-inflammatory properties. These compounds act by inhibiting leukotriene A (LTA), an enzyme responsible for the biosynthesis of leukotriene LTB, which is a crucial proinflammatory mediator. Additionally, he has developed LTA4 hydrolase inhibitors that play a vital role in therapeutic avenues, especially in treating inflammation. His inventions not only showcase his innovative spirit but also present valuable applications for therapeutic methods.

Career Highlights: Thierry Monteil has been associated with prominent companies such as Société Civile Bioprojet and Bioprojet. His career is characterized by a strong commitment to research and development in the pharmaceutical and medicinal sectors, where he has contributed towards creating impactful health solutions.

Collaborations: Throughout his career, Thierry has collaborated with distinguished colleagues, including Denis Danvy and Jean-Charles Schwartz. These partnerships have fostered a collaborative environment that has been essential for innovative exploration and the advancement of groundbreaking therapies.

Conclusion: Thierry Monteil's inventive contributions have positioned him as a significant figure in the realm of medicinal innovations. With a strong foundation in anti-inflammatory research and collaborations with various professionals in the field, he continues to pave the way for future developments that can benefit health care and therapeutic practices.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com